Ireland· IE-PA-EU/1/18/1311/001
Nerlynx 40 mg Film-coated tablet
A neratinib product containing neratinib, registered in Ireland by Pierre Fabre Medicament. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Neratinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EH02 (neratinib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Neratinib · ATC L01EH02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Neratinib
- Manufacturer
- Pierre Fabre Medicament
- Country
- Ireland (IE)
- ATC code
- L01EH02
- ATC class
- Neratinib
- Defined daily dose
- 0.24 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/18/1311/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
226 interactions on record for neratinib.
Graded by severity as the source publishes them — 97 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Neratinib · interactions on record
226 records
- 97 severe
- 123 moderate
- 6 minor
Most severe, free to view
- ClotrimazoleA01AB18severe
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Neratinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumNerlynx 40 mgPierre Fabre Médicament
- SwitzerlandNerlynx 40 mg, FilmtablettenPierre Fabre Pharma SA
- CzechiaNERLYNXPIERRE FABRE MEDICAMENT, Lavaur
- SpainNERLYNX 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPierre Fabre Medicament
- FinlandNerlynxPierre Fabre Medicament
- IcelandNerlynxPierre Fabre Medicament
- NetherlandsNerlynx 40 mg, filmomhulde tablettenPierre Fabre Medicament
- NorwayNerlynxPierre Fabre Medicament
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nerlynx
- Liechtenstein · Nerlynx
- Norway · Nerlynx
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6d04a6e0-47fd-41fc-a45a-7d70660b1717 GET /v1/drugs/6d04a6e0-47fd-41fc-a45a-7d70660b1717?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01EH02"
],
"strength": null,
"pa_number": "EU/1/18/1311/001",
"substances": [
"Neratinib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about neratinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.